Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$25.85−0.56 (-2.12%)
Close on Nov 17, 2026Market cap $12.92BP/E –Yield –
Elanco Animal Health total assets
Total assets on the balance sheet at the end of each period.
Elanco Animal Health's total assets was $13.56B at Jun 30, 2026. For fiscal 2025 it was $13.36B, up 5.9% from the year before. The highest annual figure on record is $17.69B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.36B | +5.9% |
| FY2024 | Dec 31, 2024 | $12.61B | -12.2% |
| FY2023 | Dec 31, 2023 | $14.36B | -7.3% |
| FY2022 | Dec 31, 2022 | $15.49B | -6.0% |
| FY2021 | Dec 31, 2021 | $16.48B | -6.9% |
| FY2020 | Dec 31, 2020 | $17.69B | +96.9% |
| FY2019 | Dec 31, 2019 | $8.99B | +0.3% |
| FY2018 | Dec 31, 2018 | $8.96B | +0.2% |
| FY2017 | Dec 31, 2017 | $8.94B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.56B | -1.3% |
| Q1 FY2026 | Mar 31, 2026 | $13.22B | +2.2% |
| Q4 FY2025 | Dec 31, 2025 | $13.36B | +5.9% |
| Q3 FY2025 | Sep 30, 2025 | $13.55B | +2.0% |
| Q2 FY2025 | Jun 30, 2025 | $13.74B | -0.2% |
| Q1 FY2025 | Mar 31, 2025 | $12.94B | -7.7% |
| Q4 FY2024 | Dec 31, 2024 | $12.61B | -12.2% |
| Q3 FY2024 | Sep 30, 2024 | $13.28B | -7.4% |
| Q2 FY2024 | Jun 30, 2024 | $13.76B | -12.9% |
| Q1 FY2024 | Mar 31, 2024 | $14.02B | -11.1% |
| Q4 FY2023 | Dec 31, 2023 | $14.36B | -7.3% |
| Q3 FY2023 | Sep 30, 2023 | $14.34B | -4.0% |
| Q2 FY2023 | Jun 30, 2023 | $15.80B | +1.2% |
| Q1 FY2023 | Mar 31, 2023 | $15.77B | -3.0% |
| Q4 FY2022 | Dec 31, 2022 | $15.49B | -6.0% |
| Q3 FY2022 | Sep 30, 2022 | $14.95B | -9.8% |
| Q2 FY2022 | Jun 30, 2022 | $15.60B | -7.3% |
| Q1 FY2022 | Mar 31, 2022 | $16.25B | -4.3% |
| Q4 FY2021 | Dec 31, 2021 | $16.48B | -6.9% |
| Q3 FY2021 | Sep 30, 2021 | $16.57B | -3.9% |
| Q2 FY2021 | Jun 30, 2021 | $16.83B | +70.4% |
| Q1 FY2021 | Mar 31, 2021 | $16.99B | +74.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.69B | +96.9% |
| Q3 FY2020 | Sep 30, 2020 | $17.24B | +95.3% |
| Q2 FY2020 | Jun 30, 2020 | $9.88B | +11.5% |
| Q1 FY2020 | Mar 31, 2020 | $9.73B | +11.2% |
| Q4 FY2019 | Dec 31, 2019 | $8.99B | +0.3% |
| Q3 FY2019 | Sep 30, 2019 | $8.82B | -4.2% |
| Q2 FY2019 | Jun 30, 2019 | $8.86B | -0.9% |
| Q1 FY2019 | Mar 31, 2019 | $8.75B | – |
| Q4 FY2018 | Dec 31, 2018 | $8.96B | – |
| Q3 FY2018 | Sep 30, 2018 | $9.21B | – |
| Q4 FY2017 | Dec 31, 2017 | $8.94B | – |
See a number that looks wrong?